News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Pedro C Barata: Data on novel IO-combo futibatinib+pembro
Collage photo Pedro C Barata and Vadim Koshkin
Sep 16, 2024, 11:12

Pedro C Barata: Data on novel IO-combo futibatinib+pembro

Pedro C Barata, Associate Professor at University Hospitals Seidman Cancer Center, shared on LinkedIn:

“So happy to see my friend Vadim Koshkin at the stage presenting very interesting data on novel IO-combo futibatinib+pembro especially FGFRalts. Bravo!”

Pedro C Barata

Source: Pedro C Barata/LinkedIn

 

cancer ESMO24 OncoDaily Oncology Pedro C Barata Vadim Koshkin
Special Coverage
Insight
Aug 3, 2025, 10:27
Tyler Shropshire: Nothing Short of Extraordinary
Drugs
Aug 3, 2025, 10:26
Nirogacestat (Ogsiveo) 2025: Patient Guide to Desmoid Tumor Treatment
Blog
Aug 3, 2025, 10:21
Aleix Prat: Publishing is not Enough in Biomedical Research
Blog
Aug 3, 2025, 10:08
Arutha Kulasinghe: A Non-Invasive Approach to Monitor Dynamic Changes in Tumour and Immune Signatures in NSCLC
Blog
Aug 3, 2025, 09:53
Asfand Yar Cheema: Important Guidance for Visiting Medical Students and Graduates in the U.S.
Blog
Aug 3, 2025, 09:48
David Poplack Has Recieved the 2025 Lifetime Achievement Award - SIOP
Science
Aug 3, 2025, 09:37
Karin Tollefson: Ensuring the Right Care for Those with ALK+ Lung Cancer
Career
Aug 3, 2025, 09:36
Lazar Popovic Started a New Position as a Head of Clinic for Medical Oncology at Oncology Institute of Vojvodina
Blog
Aug 3, 2025, 09:25
Jia (Jenny) Liu: The First Early Phase Trials I Have Had the Privilege of Conducting as PI
Blog
Aug 3, 2025, 08:39
Florian Lordick: How Do Early Survivors of Cancer Feel
Science
Aug 3, 2025, 07:02
Arndt Vogel: New Insights Into Metachronous Colorectal Cancer Risk in Lynch Syndrome
Science
Aug 3, 2025, 06:55
Elisabetta Bonzano: Prosigna Assay Influences Neoadjuvant Treatment Decisions in Early HR+/HER2- Breast Cancer